Ibex Wealth Advisors Makes New Investment in Bristol Myers Squibb Company $BMY

Ibex Wealth Advisors acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 74,369 shares of the biopharmaceutical company’s stock, valued at approximately $4,641,000.

Several other institutional investors have also recently bought and sold shares of BMY. BlackRock Inc. grew its holdings in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp increased its stake in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after buying an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after buying an additional 119,690 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Bristol Myers Squibb by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after buying an additional 520,330 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

These are some of the BMY news items that stood out recently:

• Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
• Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
• Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Julia Haller sold 3,800 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is owned by company insiders.

Analysts Set New Price Targets

BMY has been the topic of several research reports. Rothschild & Co Redburn upped their price target on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. raised their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Jefferies Financial Group restated a “buy” rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, October 12th. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Finally, Citigroup reiterated a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb Trading Up 1.7%

Shares of NYSE BMY traded up $1.07 during midday trading on Friday, hitting $63.39. The stock had a trading volume of 9,273,842 shares, compared to its average volume of 10,342,026. The company’s 50-day simple moving average is $61.90 and its 200 day simple moving average is $60.31. The firm has a market cap of $129.57 billion, a P/E ratio of 14.06, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the previous year, the company posted $1.63 earnings per share. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. Research analysts anticipate that Bristol Myers Squibb Company will post 6.46 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.